This graphic details the trial design behind HPTN 083 and HPTN 084, two-large scale efficacy trials testing cabotegravir, an antiretroviral formulated as an injectable for long-lasting pre- exposure prophylaxis (PrEP).
To learn more, read An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP.
- Topics:
- Accelerating Product Innovation
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!